Vancomycin-resistant enterococci

OBJECTIVE: To review vancomycin resistance in enterococci (Enterococcus faecalis and Enterococcus faecium) with respect to history, epidemiology, mechanism of resistance, and management. DATA SOURCES: A MEDLINE, IDIS, and current journal search of English-language articles on vancomycin-resistant enterococci (VRE) published between 1982 and 1994 was conducted. STUDY SELECTION: Studies and reports pertaining to vancomycin-resistant E. faecalis and E. faecium were evaluated. Case reports, cohort, epidemiologic, in vitro and in vivo studies were evaluated. DATA EXTRACTION: Reports in which vancomycin minimum inhibitory concentrations were 32 micrograms/mL or more were evaluated. DATA SYNTHESIS: Large outbreaks of VRE infection have occurred as a result of nosocomial spread. Such outbreaks have required intensive infection control procedures to limit the spread of VRE. Vancomycin resistance in E. faecalis and E. faecium has been subdivided into phenotypes, VanA and VanB. The mechanism of vancomycin resistance is caused by the production of depsipeptide D-Ala-D-Lac, which replaces D-Ala-D-Ala in the peptidoglycan pathway, thereby preventing the binding of vancomycin to D-Ala-D-Ala in the peptidoglycan cell wall. The vanA gene is associated with a transpositional element (Tn1546) that can be transferred via conjugation while most data suggest that vanB has an endogenous origin. Education, aggressive infection control practices. surveillance programs, and appropriate use of vancomycin are necessary to respond to the VRE problem. CONCLUSIONS: The prevalence of VRE has increased significantly in recent years and has become a worldwide problem. Several factors, such as prior exposure to vancomycin and antibotics (e.g., cephalosporins, antianaerobic agents), physical location in the hospital, immunosuppression, prolonged hospital stay, and VRE gastrointestinal colonization are associated with VRE infection and colonization. Antibiotic treatment of serious VRE infection depends on the phenotype. Optimal treatment of the VanA phenotype is unknown; the VanB phenotype may be treated with teicoplanin and an aminoglycoside.

This article has been cited by other articles:

				Y. Ding, R. M. Williams, and D. H. Sherman Molecular Analysis of a 4-Dimethylallyltryptophan Synthase from Malbranchea aurantiaca J. Biol. Chem., June 6, 2008; 283(23): 16068 - 16076. [Abstract] [Full Text] [PDF]

				C. Ponticelli New recommendations in the treatment of Gram-positive bacteraemia in dialysis patients Nephrol. Dial. Transplant., January 1, 2008; 23(1): 27 - 32. [Full Text] [PDF]

				G. G. Zhanel, N. M. Laing, K. A. Nichol, L. P. Palatnick, A. Noreddin, T. Hisanaga, J. L. Johnson, the NAVRESS Group, and D. J. Hoban Antibiotic activity against urinary tract infection (UTI) isolates of vancomycin-resistant enterococci (VRE): results from the 2002 North American Vancomycin Resistant Enterococci Susceptibility Study (NAVRESS) J. Antimicrob. Chemother., September 1, 2003; 52(3): 382 - 388. [Abstract] [Full Text] [PDF]

				R.-C. Mercier, C. Stumpo, and M. J. Rybak Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium J. Antimicrob. Chemother., July 1, 2002; 50(1): 19 - 24. [Abstract] [Full Text] [PDF]

				C. E. Lee, T. R. Zembower, M. A. Fotis, M. J. Postelnick, P. A. Greenberger, L. R. Peterson, and G. A. Noskin The Incidence of Antimicrobial Allergies in Hospitalized Patients: Implications Regarding Prescribing Patterns and Emerging Bacterial Resistance Arch Intern Med, October 9, 2000; 160(18): 2819 - 2822. [Abstract] [Full Text] [PDF]

				E. Torell, O. Cars, B. Olsson-Liljequist, B.-M. Hoffman, J. Lindbäck, L. G. Burman, and The Enterococcal Study Group Near Absence of Vancomycin-Resistant Enterococci but High Carriage Rates of Quinolone-Resistant Ampicillin-Resistant Enterococci among Hospitalized Patients and Nonhospitalized Individuals in Sweden J. Clin. Microbiol., November 1, 1999; 37(11): 3509 - 3513. [Abstract] [Full Text]

				F. SCHAEFER, G. KLAUS, D. E. MÜLLER-WIEFEL, and O. MEHLS Intermittent versus Continuous Intraperitoneal Glycopeptide/Ceftazidime Treatment in Children with Peritoneal Dialysis-Associated Peritonitis J. Am. Soc. Nephrol., January 1, 1999; 10(1): 136 - 145. [Abstract] [Full Text]

				C. Y. Turenne, D. J. Hoban, J. A. Karlowsky, G. G. Zhanel, and A. M. Kabani Screening of Stool Samples for Identification of Vancomycin-Resistant Enterococcus Isolates Should Include the Methyl-alpha -DGlucopyranoside Test To Differentiate Nonmotile Enterococcus gallinarum from E. faecium J. Clin. Microbiol., August 1, 1998; 36(8): 2333 - 2335. [Abstract] [Full Text]